RT Journal Article SR Electronic T1 Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.08.22268953 DO 10.1101/2022.01.08.22268953 A1 Ju, Yi A1 Lee, Wen Shi A1 Pilkington, Emily H. A1 Kelly, Hannah G. A1 Li, Shiyao A1 Selva, Kevin J. A1 Wragg, Kathleen M. A1 Subbarao, Kanta A1 Nguyen, Thi H.O. A1 Rowntree, Louise C. A1 Allen, Lilith F. A1 Bond, Katherine A1 Williamson, Deborah A. A1 Truong, Nghia P. A1 Plebanski, Magdalena A1 Kedzierska, Katherine A1 Mahanty, Siddhartha A1 Chung, Amy W. A1 Caruso, Frank A1 Wheatley, Adam K. A1 Juno, Jennifer A. A1 Kent, Stephen J. YR 2022 UL http://medrxiv.org/content/early/2022/05/11/2022.01.08.22268953.abstract AB Humans commonly have low level antibodies to poly(ethylene) glycol (PEG) due to environmental exposure. Lipid nanoparticle (LNP) mRNA vaccines for SARS-CoV-2 contain small amounts of PEG but it is not known whether PEG antibodies are enhanced by vaccination and what their impact is on particle–immune cell interactions in human blood. We studied plasma from 130 adults receiving either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) mRNA vaccines, or no SARS-CoV-2 vaccine for PEG-specific antibodies. Anti-PEG IgG was commonly detected prior to vaccination and was significantly boosted a mean of 13.1-fold (range 1.0 to 70.9) following mRNA-1273 vaccination and a mean of 1.78-fold (range 0.68 to 16.6) following BNT162b2 vaccination. Anti-PEG IgM increased 68.5-fold (range 0.9 to 377.1) and 2.64-fold (0.76 to 12.84) following mRNA-1273 and BNT162b2 vaccination, respectively. The rise in PEG-specific antibodies following mRNA-1273 vaccination was associated with a significant increase in the association of clinically relevant PEGylated LNPs with blood phagocytes ex vivo. PEG antibodies did not impact the SARS-CoV-2 specific neutralizing antibody response to vaccination. However, the elevated levels of vaccine-induced anti-PEG antibodies correlated with increased systemic reactogenicity following two doses of vaccination. We conclude that PEG-specific antibodies can be boosted by LNP mRNA-vaccination and that the rise in PEG-specific antibodies is associated with systemic reactogenicity and an increase of PEG particle–leukocyte association in human blood. The longer-term clinical impact of the increase in PEG-specific antibodies induced by lipid nanoparticle mRNA-vaccines should be monitored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Australian National Health and Medical Research Council (NHMRC) fellowship or leadership awards to S.J.K., K.K., J.A.J., A.K.W., F.C., A.W.C., D.A.W., K.S. and T.H.O.N.; RMIT Vice Chancellor Postdoctoral Fellowship to Y.J.; the Australian Medical Research Future Fund award #2005544 to K.K., S.J.K., J.A.J., A.K.W., A.W.C. and D.A.W.; Australian Research Council awards DP210103114 and DP200100231 to F.C., N.P.T., S.J.K., Y.J. and A.K.W., and NHMRC award 1149990 to S.J.K. and F.C.. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects provided written informed consent and the studies were approved by the University of Melbourne human research and ethics committee (approvals 2056689, 21198153983 and 2021-21626-15756-1) and the Royal Melbourne Hospital human research and ethics committee (approvals 6309/MH-2020, 2013.290 and 68355/MH-2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supporting information